Perampanel as a second-line therapy to midazolam reduces soman-induced status epilepticus and neurodegeneration in rats.

ABSTRACT:

Objective

A benzodiazepine (diazepam or midazolam) is one of the current standards of care therapies to effectively terminate organophosphorus nerve agent-induced status epilepticus when administered shortly after onset. Preclinical studies showed that benzodiazepines were less effective in stopping status epilepticus when treatment was delayed up to 30 min from the time of organophosphorus exposure, highlighting the need for adjuncts to midazolam in a delayed treatment scenario. In this study, we evaluated the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist perampanel for efficacy as a second-line antiseizure medication against soman-induced benzodiazepine-refractory status epilepticus.

Methods

Adult male Sprague-Dawley rats were exposed

SUBMITTER: Steier HG 

PROVIDER: S-EPMC12362163 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature